DelveInsight’s, “ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC) Pipeline Insight 2024” report provides comprehensive insights about 6+ companies and 7+ pipeline drugs in ALK-positive Non-Small Cell Lung Cancer pipeline landscape. It covers the ALK-positive Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ALK-positive Non-Small Cell Lung Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in ALK-positive Non-Small Cell Lung Cancer Research. Learn more about our innovative pipeline today! @ ALK-positive Non-Small Cell Lung Cancer Pipeline Outlook
Key Takeaways from the ALK-positive Non-Small Cell Lung Cancer Pipeline Report
- June 2024:- Pfizer- Single-Arm Study of Lorlatinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) Whose Disease Progressed After One Prior Second-Generation ALK Tyrosine Kinase Inhibitor (TKI). The purpose of this clinical trial is to learn whether the study medicine (called lorlatinib) is safe and effective for the treatment of non-small cell lung cancer that is caused by an abnormal anaplastic lymphoma kinase (ALK) gene.
- June 2024:- Takeda- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®). The drug being tested in this study is called brigatinib. Brigatinib has been demonstrated to benefit people with anaplastic lymphoma kinase-positive (ALK+) NSCLC.
- June 2024:- Hoffmann-La Roche- The purpose of this study is to provide continued treatment with alectinib or crizotinib as applicable to participants with ALK- or RET positive cancer who were previously enrolled in any Roche-sponsored alectinib study and who are deriving continued clinical benefit from alectinib or crizotinib in the parent trial at the time of parent trial closure.
- June 2024:- AstraZeneca- Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments. A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy.
- DelveInsight’s ALK-positive Non-Small Cell Lung Cancer pipeline report depicts a robust space with 6+ active players working to develop 7+ pipeline therapies for ALK-positive Non-Small Cell Lung Cancer treatment.
- The leading ALK-positive Non-Small Cell Lung Cancer Companies such as Nuvalent, Shouyao Holdings, Xuanzhu Biopharmaceutical, Fochon Pharmaceutical, and others.
- Promising ALK-positive Non-Small Cell Lung Cancer Therapies such as Crizotinib, XZP-3621, Gefitinib, Savolitinib, Osimertinib, TGRX-326, and others.
Stay informed about the cutting-edge advancements in ALK-positive Non-Small Cell Lung Cancer Treatments. Download for updates and be a part of the revolution in oncology care @ ALK-positive Non-Small Cell Lung Cancer Clinical Trials Assessment
ALK-positive Non-Small Cell Lung Cancer Emerging Drugs Profile
- SY-3505: Shouyao Holdings
Ficonalkib (SY-3505) is a highly potent, adenosine triphosphate-competitive, CNS-penetrant, 3rd-gen ALK TKI. In vitro kinase assay revealed that ficonalkib exhibits potent inhibition against both wild-type ALK and a diverse spectrum of mutants observed in patients resistant to 1st- and 2nd-gen ALK TKI, including L1196M, G1202R, F1174L, G1269S, and R1275Q20. The drug exhibits high kinase selectivity and has very weak inhibition on tropomyosin receptor kinase (TRK). The drug is currently being evaluated under Phase III clinical trials for the treatment of NSCLC.
- APG-2449: Ascentage Pharma
APG-2449 is an orally available, small-molecule FAK/ALK/ROS1 TKI and the first China-developed third-generation ALK inhibitor entering clinical development. The updated results at the ASCO indicated favorable safety and promising antitumor activity in patients with NSCLC, and the preliminary efficacy observed in patients who were resistant to second-generation ALK inhibitors was particularly encouraging. APG-2449 is currently being evaluated in Phase I clinical trial for Non-Small Cell Lung Cancer.
Learn more about ALK-positive Non-Small Cell Lung Cancer Drugs opportunities in our groundbreaking ALK-positive Non-Small Cell Lung Cancer Research and development projects @ ALK-positive Non-Small Cell Lung Cancer Unmet Needs
ALK-positive Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
ALK-positive Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
Discover the latest advancements in ALK-positive Non-Small Cell Lung Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ ALK-positive Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives
Scope of the ALK-positive Non-Small Cell Lung Cancer Pipeline Report
- Coverage- Global
- ALK-positive Non-Small Cell Lung Cancer Companies- Nuvalent, Shouyao Holdings, Xuanzhu Biopharmaceutical, Fochon Pharmaceutical, and others.
- ALK-positive Non-Small Cell Lung Cancer Therapies- Crizotinib, XZP-3621, Gefitinib, Savolitinib, Osimertinib, TGRX-326, and others.
- ALK-positive Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- ALK-positive Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of ALK-positive Non-Small Cell Lung Cancer Pipeline on our website @ ALK-positive Non-Small Cell Lung Cancer Drugs and Companies
Table of Content
- Introduction
- Executive Summary
- ALK Positive Non-Small Cell Lung Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- ALK Positive Non-Small Cell Lung Cancer – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- SY-3505: Shouyao Holdings
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Product Name: Company Name
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- APG-2449: Ascentage Pharma
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- ALK Positive Non-Small Cell Lung Cancer – Collaborations Assessment- Licensing / Partnering / Funding
- ALK Positive Non-Small Cell Lung Cancer – Unmet Needs
- ALK Positive Non-Small Cell Lung Cancer – Market Drivers and Barriers
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: ALK-positive Non-Small Cell Lung Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight